Recursion Pharmaceuticals, Inc. RXRX
3.88 USD +0.20 (+5.43%)
At closeNov 4, 2026, 7:56 PM EST
3.85 -0.03 -0.77%
After hours · Nov 4, 7:56 PM ET
3.72 Day range 4.01
2.84 52-week range 5.00
- YTD
- -5.13%
- 1 year
- -22.40%
News
zacks.com RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway Recursion highlights promising clinical data for REC-4881 and REC-1245, beats Q3 earnings estimates and extends its cash runway into 2029 through disciplined spending.
seekingalpha.com Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Najat Khan - CEO, President & Director Vicki Goodman - Chief Medical Officer Ben…
marketbeat.com What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call Recursion Pharmaceuticals NASDAQ: RXRX reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor…
zacks.com Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.
zacks.com Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.36 per share a year ago.
globenewswire.com Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for…
globenewswire.com New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps Denver, Colorado, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced new positive Phase…
benzinga.com Recursion Appoints Fred Hassan As Board Chair, Effective Oct. 31 Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair,…
globenewswire.com Recursion Appoints Fred Hassan as Chair of the Board Salt Lake City, UT, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board…
fool.com 1 Big Winner and 1 Loser From the Upcoming Anthropic IPO Broadcom has a multi-year agreement with Anthropic that's worth tens of billions of dollars. Anthropic will undercut Recursion Pharmaceuticals' competitive advantage.
zacks.com Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.03, moving 4.95% from the previous trading session.
zacks.com Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.
zacks.com Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com Why Investors Need to Take Advantage of These 2 Medical Stocks Now Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
zacks.com Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.8, signifying a +2.7% move from its prior day's close.
benzinga.com ParaZero Technologies To Provide Earnings Updates And REC-4881 Data As Well As KOL And Patient Panels On Tuesday, November 3, 2026 Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, announced today it will provide business…
globenewswire.com Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 Salt Lake City, UT, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically…
zacks.com Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing Recursion Pharmaceuticals (RXRX) reached $3.66 at the closing of the latest trading day, reflecting a +1.39% change compared to its last close.
defenseworld.net Recursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLC Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Needham and Company LLC in a research note issued to investors on Monday,…- benzinga.com Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
benzinga.com Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and a $10 million Sanofi milestone payment.
globenewswire.com Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class…
benzinga.com Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027 Recursion Announces Sanofi Options Potential First-in-Class Immunology Development CandidateOn October 15, 2026, Recursion announced that Sanofi has optioned the first development candidate from the…
globenewswire.com Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and…
benzinga.com Recursion Commences $200M Common Stock Offering Of 61,540,000 Shares Of Its Class A Common Stock At A Price Of $3.25/Share Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced a $200 million underwritten…
globenewswire.com Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve…
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com Squeeze Watch: 10 Stocks With Over 33% Short Interest Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
benzinga.com Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new…
benzinga.com Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is…
benzinga.com Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
benzinga.com Jim Cramer: These Utilities Stocks Are 'Oversold,' Fastly 'Back From The Abyss' Cramer likes Vistra and Constellation, but not NextEra. Recursion and Fastly reported weak earnings, Huntington raised sales guidance.- benzinga.com Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over…
benzinga.com Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A decline, signaling a shift in AI adoption.- benzinga.com Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5 Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and raises the price target from $5 to $5.5.
benzinga.com Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.- benzinga.com Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Recursion Pharmaceuticals Q1 EPS $(0.22) Beats $(0.27) Estimate, Sales $6.472M Miss $15.777M Estimate Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.27) by 18.52 percent. This is a 56 percent increase over losses…
- benzinga.com JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10 JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $11 to $10.
- benzinga.com Citeline Announces Expanded Strategic Partnership With Recursion, Advancing AI-Enabled ClinTech Platform Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a leading tech-bio company decoding biology…
benzinga.com B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6 B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral and lowers the price target from $7 to $6.
benzinga.com Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
benzinga.com What's Behind The Jump In Recursion Pharmaceuticals Stock? Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell.
benzinga.com Recursion Pharmaceuticals Q4 Earnings Report: What Investors Need to Know - benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025 ARK's 2025 winners included Robinhood, AMD and Palantir, while its losers were The Trade Desk, Recursion and Twist.
benzinga.com Recursion Pharmaceuticals's Earnings Outlook 
benzinga.com Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby, CoreWeave, Salesforce, Lucid and more.
benzinga.com Palo Alto, Fiverr International, Axcelis Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session